Phase 2Not yet recruitingPriority 2 · High priorityNCT06702605
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Plain-language summary
This trial is testing XNW5004 tablets (an investigational oral drug) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
XNW5004 tablets (DRUG): XNW5004 will be administered orally as tablets.
XNW5004 tablets
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details